Differential regulation of human apolipoprotein AI and high-density lipoprotein by fenofibrate in hapoAI and hapoAI-CIII-AIV transgenic mice

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1811, Issue 2, 2011, Pages 76-83

  Srivastava, Rai Ajit K ^a   He, Shirley ^a,b   Newton, Roger S ^a  

^a Esperion Therapeutics Inc   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Apolipoprotein A1; Cholic acid; Fenofibrate; HDL; Phospholipid transfer protein; SR BI

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A4; APOLIPOPROTEIN C3; CHOLIC ACID; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; PHOSPHOLIPID TRANSFER PROTEIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHROMOSOME 11; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SEQUENCE ANALYSIS; TRANSGENE; UPREGULATION;

ANIMALS; ANTIGENS, CD36; APOLIPOPROTEIN A-I; CARRIER PROTEINS; CHOLIC ACID; FENOFIBRATE; HUMANS; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS, HDL; MICE; MICE, TRANSGENIC; TRIGLYCERIDES;

MUS; MUS MUSCULUS;

EID: 78650589827     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2010.11.004     Document Type: Article

References (50)

1. American Heart Association Heart disease and stroke statistics-2007 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 115 2007 e69 e171
2. P. Linsel-Nitschke, and A.R. Tall HDL as a target in the treatment of atherosclerotic cardiovascular disease Nat. Rev. Drug Discov. 4 2005 193 205
3. C.P. Cannon, E. Braunwald, C.H. McCabe, D.J. Rader, J.L. Rouleau, R. Belder, S.V. Joyal, K.A. Hill, M.A. Pfeffer, and A.M. Skene Intensive versus moderate lipid lowering with statins after acute coronary syndromes N. Engl. J. Med. 350 2004 1495 1504
4. U. Goldbourt, S. Yaari, and J.H. Medalie Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality: a 21-year follow-up of 8000 men Arterioscler. Thromb. Vasc. Biol. 17 1997 107 113
5. D.J. Gordon, J. Knoke, J.L. Probstfield, R. Superko, and H.A. Tyroler High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial Circulation 74 1986 1217 1225
6. D.J. Gordon, J.L. Probstfield, R.J. Garrison, J.D. Neaton, W.P. Castelli, J.D. Knoke, D.R. Jacobs Jr., S. Bangdiwala, and H.A. Tyroler High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies Circulation 79 1989 8 15
7. P.N. Hopkins, G. Heiss, R.C. Ellison, M.A. Province, J.S. Pankow, J.H. Eckfeldt, and S.C. Hunt Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: a case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study Circulation 108 2003 519 523
8. J.J. Genest, J.R. McNamara, D.N. Salem, and E.J. Schaefer Prevalence of risk factors in men with premature coronary artery disease Am. J. Cardiol. 67 1991 1185 1189
9. D.A.I.S. Investigators Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study Lancet 357 2001 905 910
10. M.H. Frick, O. Elo, K. Haapa, O.P. Heinonen, P. Heinsalmi, P. Helo, J.K. Huttunen, P. Kaitaniemi, P. Koskinen, and V. Manninen Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease N. Engl. J. Med. 317 1987 1237 1245
11. H.B. Rubins, S.J. Robins, D. Collins, C.L. Fye, J.W. Anderson, M.B. Elam, F.H. Faas, E. Linares, E.J. Schaefer, and G. Schectman Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group N. Engl. J. Med. 341 1999 410 418
12. G.M. Reaven Pathophysiology of insulin resistance in human disease Physiol. Rev. 75 1995 473 486
13. D.E. Moller, and K.D. Kaufman Metabolic syndrome: a clinical and molecular perspective Annu. Rev. Med. 56 2005 45 62
14. P. Hossain, B. Kawar, and M. El Nahas Obesity and diabetes in the developing world-a growing challenge N. Engl. J. Med. 365 2007 213 215
15. K. Adeli, C. Taghibiglou, S.C. Van Iderstine, and G.F. Lewis Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance Trends Cardiovasc. Med. 11 2001 170 176 (Review)
16. C. Taghibiglou, A. Carpentier, S.C. Van Iderstine, B. Chen, D. Rudy, A. Aiton, G.F. Lewis, and K. Adeli Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance. Evidence for enhanced lipoprotein assembly, reduced intracellular ApoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model J. Biol. Chem. 275 2000 8416 8425
17. R.A.K. Srivastava, and N. Srivastava High-density lipoprotein, apolipoprotein A-I, and coronary artery disease. Review Mol. Cell. Biochem. 209 2000 131 144 (Review)
18. G. Steiner Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study Lancet 357 2001 905 910
19. S. Fazio, and M.F. Linton The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy Curr. Atheroscler. Rep. 6 2004 148 157 (Review)
20. R.A.K. Srivastava, R. Jahagirdar, S. Azhar, S. Sharma, and C.L. Bisgaier Peroxisome proliferator-activated receptor-α-selective ligand reduces adiposity, improves insulin sensitivity, and inhibits atherosclerosis in LDL receptor-deficient mice Mol. Cell. Biochem. 285 2006 35 50
21. K.S. Frederiksen, E.M. Wulff, P. Sauerberg, J.P. Mogensen, L. Jeppesen, and J. Fleckner Prediction of PPAR-alpha ligand-mediated physiological changes using gene expression profiles J. Lipid Res. 45 2004 592 601
22. B. Huang, P. Wu, M.M. Bowker-Kinley, and R.A. Harris Regulation of pyruvate dehydrogenase kinase expression by peroxisome proliferator-activated receptor-alpha ligands, glucocorticoids, and insulin Diabetes 51 2002 276 283
23. H. Duez, B. Lefebvre, P. Poulain, I. Pineda Torra, F. Percevault, G. Luc, J.M. Peters, F.J. Gonzalez, R. Gineste, S. Helleboid, J.C. Fruchart, C. Fievet, P. Lefebvre, and B. Staels Regulation of human ApoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor-α modulation Arterioscler. Thromb. Vasc. Biol. 225 2004 585 591
24. L. Berthou, N. Duverger, F. Emmanuel, S. Langouet, J. Auwerx, A. Guillouzo, J.C. Fruchart, E. Rubin, P. Denefle, B. Staels, and D. Branellec Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice J. Clin. Invest. 97 1997 2408 2416
25. R.A.K. Srivastava Estrogen-induced regulation of the ABCA1 in mice: a possible mechanism of atheroprotection by estrogen Mol. Cell. Biochem. 240 2002 67 73
26. E.M. Rubin, B.Y. Ishida, S.M. Clift, and R.M. Krauss Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses Proc. Natl Acad. Sci. USA 88 1991 1991 434 438
27. L. Vergnes, N. Baroukh, M.A. Ostos, G. Castro, N. Duverger, M.N. Nanjee, J. Najib, J. Fruchart, N.E. Miller, M.M. Zakin, and A. Ochoa Expression of human apolipoprotein A-I/C-III/A-IV gene cluster in mice induces hyperlipidemia but reduces atherogenesis Arterioscler. Thromb. Vasc. Biol. 20 2000 2267
28. R.A.K. Srivastava, N. Srivastava, and M. Averna Dietary cholic acid lowers plasma apolipoprotein AI primarily by transcriptional mechanism Eur. J. Biochem. 267 2000 4272 4280
29. R.A.K. Srivastava, M. Averna, N. Srivastava, and M.E. Pape Dietary cholic acid increases plasma levels of apolipoprotein B in mice by posttranscriptional mechanism Int. J. Biochem. Cell Biol. Lond. 33 2001 1215 1226
30. R.A.K. Srivastava, D. Baumann, and G. Schonfeld In vivo regulation of low density lipoprotein receptor by estrogen differs at the post-transcriptional level in rat and mouse Eur. J. Biochem. 216 1993 527 538
31. R.A.K. Srivastava, N. Srivastava, and G. Schonfeld Expression of low density lipoprotein receptor, apolipoprotein AI, AII and AIV in various rat organs utilizing an efficient and rapid method for RNA isolation Biochem. Int. 27 1992 85 95
32. H. Speijer, J.E. Groener, E. van Ramshorst, and A. van Tol Different locations of cholesteryl ester transfer protein and phospholipid transfer protein activities in plasma Atherosclerosis 90 1991 159 168
33. K. Aalto-Setala, E.A. Fisher, X. Chen, T. Chajek-Shaul, T. Hayek, R. Zechner, A. Walsh, R. Ramakrishnan, H.N. Ginsberg, and J.L. Breslow Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apoCIII and reduced apoE on the particles J Clin Invest 90 1992 1889 1900
34. R.A.K. Srivastava, J. Tang, E.S. Krul, B. Pfleger, R.T. Kitchens, and G. Schonfeld Dietary fatty acids and cholesterol differ in their effects on the in vivo regulation of apoAI and apoAII gene expressions in inbred strains of mice Biochim. Biophys. Acta 1125 1992 251 261
35. M. Bouly, D. Masson, B. Gross, X.C. Jiang, C. Fievet, G. Castro, A.R. Tall, J.C. Fruchart, B. Staels, L. Lagrost, and G. Luc Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate J. Biol. Chem. 276 2001 25841 25847
36. M.C. Cheung, G. Wolfbauer, H. Deguchi, J.A. Fernández, and J.H. Griffin Human plasma phospholipid transfer protein specific activity is correlated with HDL size: implications for lipoprotein physiology Biochim. Biophys. Acta, Mol. Cell Biol. Lipids 1791 2009 206 211
37. N.Q. Cui, S.K. Zhang, Y.F. Cui, D.H. Li, C. Chen, and X.Z. Wu Overexpression of sterol carrier protein-2 mRNA in patients with cholesterol gallstones Hepatobiliary Pancreat. Dis. Int. 4 2005 117 120
38. R. Mukherjee, K.T. Locke, B. Miao, D. Meyers, H. Monshizadegan, R. Zhang, D. Search, D. Grimm, M. Flynn, M. Kevin, K.M. O'Malley, L. Zhang, J. Li, Y. Shi, L.J. Kennedy, M. Blanar, P.T. Cheng, J. Tino, and R.A.K. Srivastava Novel PPARα agonists lower LDL and triglycerides, raise HDL and synergistically increase cholesterol excretion with an LXR agonist J. Pharmacol. Exp. Ther. 327 2008 716 726
39. J.S. Millar, D. Duffy, R. Gadi, L.T. Bloedon, R.L. Dunbar, M.L. Wolfe, R. Movva, A. Shah, I.V. Fuki, M. McCoy, C.J. Harris, M. Wang, D.C. Howey, and D.J. Rader The potent and selective PPAR-α agonist LY518674 upregulates both apoAI production and catabolism in human subjects with the netabolic syndrome Arterioscler. Thromb. Vasc. Biol. 29 2009 140 146
40. S. Bilz, S. Wagner, M. Schmitz, A. Bedynek, U. Keller, and T. Demant Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia J. Lipid Res. 45 2004 174 185
41. J.P. Singh, R. Kauffman, W. Bensch, G. Wang, P. McClelland, J. Bean, C. Montrose, N. Mantlo, A. Wagle. Identification of a novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-2-(4-{3-[1-(4- methylbenzyl)-5-oxo-4, 5-dihydro-1H-1, 2, 4-triazol-3-yl]propyl}phenoxy) propanoic acid (LY518674), that produces marked changes in serum lipids and apolipoprotein A-1 expression, Mol. Pharmacol. 68 (2005) 763-768.
42. T. Hayek, Y. Ito, N. Azrolan, R.B. Verdery, K. Aalto Setala, A. Walsh, and J.L. Breslow Dietary fat increases high density lipoprotein (HDL) levels both by increasing the transport rates and decreasing the fractional catabolic rates of HDL cholesterol ester and apolipoprotein (Apo) A-I. Presentation of a new animal model and mechanistic studies in human Apo A-I transgenic and control mice J. Clin. Invest. 91 1993 1665 1671
43. R.A.K. Srivastava Saturated fatty acid, but not cholesterol, regulates apolipoprotein AI gene expression by posttranscriptional mechanism Biochem. Mol. Biol. Int. 34 1994 393 402
44. Y. Ito, N. Azrolan, A. O'Connell, A. Walsh, and J.L. Breslow Hypertriglyceridemia as a result of human apoCIII gene expression in transgenic mice Science 249 1990 790 793
45. B. Lamarche, K.D. Uffelman, A. Carpentier, J.S. Cohn, G. Steiner, P.H. Barrett, and G.F. Lewis Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men J. Clin. Invest. 103 1999 1191 1199
46. L.R. Brunham, J.K. Kruit, J. Iqbal, C. Fievet, J.M. Timmins, T.D. Pape, B.A. Coburn, N. Bissada, B. Staels, A.K. Groen, M.M. Hussain, J.S. Parks, F. Kuipers, and M.R. Hayden Intestinal ABCA1 directly contributes to HDL biogenesis in vivo J. Clin. Invest. 116 2006 1052 1062
47. K.F. Kozarsky, M.H. Donahee, A. Rigotti, S.N. Iqbal, E.R. Edelman, and M. Krieger Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels Nature 387 1997 414 417
48. R.A.K. Srivastava Estrogen-induced regulation of the ATP-binding cassette transporter A1 (ABCA1) in mice: a possible mechanism of atheroprotection by estrogen Mol. Cell. Biochem. 240 2002 67 73
49. Y. Zhang, L. Yin, J. Anderson, H. Ma, F.J. Ganzalez, and T.M. Willson Identification of novel pathways that control farnexoid X receptor-mediated hypocholesterolemia J. Biol. Chem. 285 2010 3035 3043
50. P. Mardones, A. Pilon, M. Bouly, D. Duran, T. Nishimoto, H. Arai, K.F. Kozarsky, M. Altayo, J.F. Miquel, G. Luc, V. Clavey, B. Staels, and A. Rigotti Fibrates down-regulate hepatic scavenger receptor class B type I protein expression in mice J. Biol. Chem. 278 2003 7884 7890